BioSpace News Archive

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 901,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.

Voyager Therapeutics, Inc. has entered into employment agreements with Peter Pfreundschuh and another newly hired employee that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September and October.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 2:00 p.m. ET in New York City.

T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the execution of a territory exclusive distribution agreement in the Baltic Region, including Lithuania, Latvia, and Estonia.

Virios Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) announces that pursuant to the Company’s existing Stock Option Plan, a total of 1,000,000 incentive stock options have been granted to a consultant of the Company

NovaBay® Pharmaceuticals, Inc. announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders: Over the past year, we have successfully transformed NovaBay from a single product company into a larger organization with three brands in three distinct market segments.

Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in September 2022.